No abstract available.
Reticulocytes*

No abstract available.
Calibration* ; Reticulocytes*

No abstract available.
Reticulocyte Count* ; Reticulocytes*

No abstract available.
Reticulocyte Count* ; Reticulocytes*

BACKGROUND: Reticulocyte counts provide clinically useful informations and the most widely used method for counting reticulocytes is a manual microscopic procedure. Although manual method is inexpensive and relatively simple to perform, it is labor intensive and imprecise. So, more rapid and more reproducible methods are needed. METHODS: Reticulocyte counts on 96 blood samples were performed by conventional manual method, H*3 RTX(TM)(Bayer, U.S.A.), and FACScan(TM)(Beckon Dickinson, U.S.A.). The changes of reticulocyte count after storage of samples and certain time intervals after preparation were also examined. RESULTS: Reticulocyte counts(%) by manual method, H*3 RTX(TM), and FACScanM were 2.05+/-2.16, 1.95+/-2.24 and 2.51+/-1.94, respectively. There was no statistically significant differences between manual counting and H*3 RTX(TM)(P>0.05). However, there were significant differences between H*3 RTX(TM) and FACScan(TM), manual counting and FACScan(TM)(P<0.05). Correlation coefficients of three comparisons were all above 0.920. Statistically not confirmed the reticulocytosis sample showed decreasing tendency of reticuocyte count by H*3 RTX(TM) after storage of the sample and prepared sample and others were relatively stable in H*3 RTX(TM)and FACScan(TM). CONCLUSIONS: The result of the mean difference between H*3 RTX(TM) and manual counting is statistically insignificant. So, the H*3 RTX(TM)can be used interchangeably with manual counting atter consideration of cost-effectiveness.
Reticulocyte Count ; Reticulocytes* ; Reticulocytosis

Humans ; Reticulocyte Count ; Reticulocytes

Transfusion requirement or hemoglobin level has been a major indicator of the erythropoiesis of CRF patients. However, the more objective and earlier detectable parameters to monitor the erythropoiesis has been required. We investigated the significance of immature reticulocyte count(IRC) with flowcytometry in CRF patients as a convenient index of erythropoietin(EPO) therapy. We evaluated CRF patients undergoing hemodialysis(n=35) and normal control group(n=14). The 26 patients of CRF have been under EPO therapy, the others(n=9) have not been under therapy. 1) The response of IRC to EPO therapy : IRC increased daily 4.95% in average upto 3rd day and decreased daily 3.7% in average since then. 2) The similar IRC was maintained in similar hemoglobin state : IRC, total reticulocyte count(TRC) and hemoglobin were compared between CRF patients with low dose EPO therapy and those who weren't needed EPO administration from the beginning. 3) The increase of IRC depends on the dose of EPO : 4) Correlation between IRC and other hematologic parameters : IRC was significantly correlated with TRC and serum iron level(R value : 0.736, 0.522 respectively). Taken together, these results suggest that maintenance of IRC level, 8-10%, was necessary at a minimum to obtain 8g/dL of hemoglobin level. However, IRC level could be readjusted more than 20% with higher EPO therapy to maintain 8g/dL of hemoglobin in severe case. In conclusion, the measurement of IRC in CRF is clinically more objective, useful, earlier indicator for estimating erythropoiesis than hemoglobin and TRC.
Erythropoiesis* ; Humans ; Iron ; Kidney Failure, Chronic ; Reticulocyte Count* ; Reticulocytes*

Anemia in myelodysplastic syndrome (MDS) is accompanied by reticulocytopenia in most patients. Reticulocytosis, when present, is generally less than appropriate to the degree of anemia and rarely exceeds 10%. In this report, three patients with MDS with persistent reticulocytosis are presented. In vitro reticulocyte survival studies have suggested that the reticulocytosis was caused by delay in maturation of the reticulocytes. Anemia with reticulocytosis, mimicking hemolytic disease, may be an unusual presentation of myelodysplastic syndrome, but, we emphasize that MDS should be included in the differential diagnosis of every patient presenting with anemia and high reticulocyte count. In vitro reticulotye survival study is easy to assess and valuable to diagnose this disease entity.
Anemia ; Diagnosis, Differential ; Humans ; Myelodysplastic Syndromes* ; Reticulocyte Count ; Reticulocytes* ; Reticulocytosis

OBJECTIVE: To research the changes of blood parameters on different time points after micro-rHuEPO injection on young men and hope to provide evidences for Athletic Biological Passport (ABP) using in the detection of blood doping. METHODS: Fourteen health young men were injected with micro-rHuEPO for 7 weeks, twice per one week.The subjects were treated with ferralia 105 mg every day during the injections.The control group was administrated with the same volume of saline solution injection and placebo 105 mg.The blood parameters (red blood cell, hemoglobin, reticulocyte, total hemoglobin, plasma volume, etc) were tested 11 times (7 days before the first injection, 3, 10, 17, 24, 31, 38 and 45 days after the first injection, 1, 2 and 3 weeks post the seventh week of last injection).By analyzed these total and concentration parameters, hope to know the effective of two kinds of parameters on ABP. RESULTS: The levels of RBC and[Hb] were increased sharply after two weeks of injection and reached the peak in 5-6 weeks (9-10%, <0.01).It sustained till 3 weeks after the last injection.Total hemoglobin was increased significantly during the whole procedure of injections and reached the peak in week 5 (10%, <0.01) till 1 week after the last injection.Red blood cell volume was increased with the EPO injection and reached the peak in week 5 (<0.01), but blood volume wasn't increased significantly.Plasma volume was decreased with EPO injection and it was hemoconcentration. CONCLUSIONS It can enhance the total and concentration parameters through 7-week micro-rHuEPO injections and the total haemoglobin is more sensitive.So tHb can be used to detect blood doping in ABP.At the end of the last injection, the total blood parameters, such as the total hemoglobin, returned to normal, while the concentration index remained highly, possibly as a result of blood concentration.
Doping in Sports ; Erythropoietin ; Hemoglobins ; Humans ; Male ; Recombinant Proteins ; Reticulocytes ; Sports

Objective: To reveal the compensatory features of bone marrow (BM) erythropoiesis in hereditary spherocytosis (HS) and to explore the effect of diferent hemoglobin levels on this compensation. Methods: Clinical and laboratory data of patients with HS were collected, and the peripheral blood absolute reticulocytes counts value was taken as the surrogate parameter to evaluate the ability of erythropoiesis compensation. BM erythropoiesis compensation in HS with diferent degrees of anemia were evaluated. Results: ①Three hundred and two patients were enrolled, including 115 with compensated hemolytic disease, 74 with mild anemia, 90 with moderate anemia, and 23 with severe anemia. ②Hemoglobin (HGB) was negatively correlated with serum erythropoietin in the decompensated hemolytic anemia group (EPO; rs=-0.585, P<0.001) . ③The median absolute reticulocyte count (ARC) of HS patients was 0.34 (0.27, 0.44) ×10(12)/L, up to 4.25 times that of normal people. The maximum ARC was 0.81×10(12)/L, about 10 times that of normal people. The median ARC of patients with compensated hemolytic disease was 0.29 (0.22, 0.38) ×10(12)/L, up to 3.63 times that of normal people. The median ARC of patients with hemolytic anemia was 0.38 (0.30, 0.46) ×10(12)/L, which was significantly higher than the patients with compensated hemolytic disease, up to 4.75 times that of normal people (z=4.999, P=0.003) . ④ ARC was negatively correlated with HGB in the compensated hemolytic disease group (rs=-0.177, P=0.002) and positively correlated with HGB in the decompensated hemolytic anemia group (rs=0.191, P=0.009) . There was no significant difference in the ARC among patients with mild, moderate, and severe anemia (χ(2)=4.588, P=0.101) . ⑤The median immature reticulocyte production index of the mild, moderate, and severe anemia groups was 13.1% (9.1%, 18.4%) , 17.0% (13.4%, 20.8%) , and 17.8% (14.6%, 21.8%) , respectively; the mild anemia group had lower index values than the moderate and severe anemia groups (P(adj) values were both<0.05) , but there was no significant difference between the latter groups (P(adj)=1.000) . The median immature reticulocyte count of patients in the mild, moderate, and severe groups was 5.09 (2.60, 7.74) ×10(10)/L, 6.24 (4.34, 8.83) ×10(10)/L, and 7.00 (3.07, 8.22) ×10(10)/L, respectively; there was no significant difference among the groups (χ(2)=3.081, P=0.214) . Conclusion: HGB can be maintained at a normal level through bone marrow erythropoiesis, while red blood cells are reduced in HS. However, once anemia develops, the bone marrow exerts its maximum erythropoiesis capacity and does not increase, regardless of anemia aggravation or serum EPO increase.
Bone Marrow ; Erythropoiesis ; Humans ; Reticulocyte Count ; Reticulocytes ; Spherocytosis, Hereditary